ClinicalTrials.gg
CompletedNCT04510194Updated Apr 24, 2026Results posted

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

A Phase 3 interventional study of Metformin and Placebo in Covid19 and SARS-CoV Infection, sponsored by University of Minnesota. Completed at 7 sites in United States. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by University of Minnesota · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,323
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in COVID-19 by University of Minnesota — none open to participants now, none under way, none of them phase 3. COVID-19 · University of Minnesota.

Enrollment
2nd of 15
1,323 · median 285
Started
2021
with 4 others
Phase 3
6 of 21
none open now
Registered
10th of 21
by date

Among the 21 studies in COVID-19 by University of Minnesota, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2021, is one of 6 in phase 3, and was the 10th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 21 studies in COVID-19 by University of Minnesota is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in COVID-19 by University of Minnesota as a file.
02

Study summary

  1. The purpose of this trial is to conduct a 2x3 factorial randomized trials, which efficiently allows the parallel conduct of three randomized trials to understand whether metformin, ivermectin, or fluvoxamine, is superior to placebo for preventing Covid-19 disease progression in non-hospitalized adults with SARS- CoV-2 infection.
  2. To understand if the active treatment arms are superior to placebo in improving viral load, serologic markers associated with Covid-19, and gut microbiome in non-hospitalized adults with SARS-CoV-2 infection.
  3. To understand if any of the active treatment arms prevent long-covid syndrome, PASC (post-acute sequelae of SARS-CoV-2 infection).
Read the detailed description

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly spreading viral infection causing COVID-19 disease. There currently is no definitive preventive or early outpatient treatment therapy for Covid-19. Study study assess 3 existing generic medications: metformin, fluvoxamine, and ivermectin.

Metformin: in-silico, in-vitro, ex-vivo tissue assays suggest that metformin inhibits viral replication of SARS-CoV-2 virus (Castle et al; Gordon et al; and Schaller et al). Several retrospective cohort analyses have suggested an association between taking metformin prior to SARS-CoV-2 infection and less severe outcomes. Kow, J Med Virol conducted a meta analysis, with an overall odds ratio for mortality of 0.62 (0.43-0.89). Gordon et al found decreased SARS-CoV-2 and increased cell viability with metformin in vitro. (Gordon et al, Nature). While anti-viral activity may be contributing to the observational associations of reduced severity of Covid-19, metformin has a proven history of beneficial immune-modulatory effects, including on CRP, IL-6 and TNF-alpha, neutrophil extracellular traps, and improved T cell immunity. Outpatient metformin use has now been associated with lower IL-6, CRP, and neutrophil-lymphocyte ratio in persons with Covid-19 (Lou et al, Diabetes Care 2020).

Fluvoxamine: appears to have anti-inflammatory effects in SARS-CoV-2 infection. There is evidence that SARS-CoV-2 infection causes ER stress and activates pathways of unfolded protein response. Sigma-1 receptor (S1R) is an ER chaperone protein that regulates cytokine production through interaction with IRE1. Fluvoxamine is a selective serotonin reuptake inhibitor that is a powerful S1R agonist. Fluvoxamine has previously been shown to protect mice from septic shock and reduce the inflammatory response. There is potential for fluvoxamine as an immunomodulatory treatment for SARS-Cov-2. Fluvoxamine in CACO2 cells infected with SARS-Cov-2 had a reduction in production of a subset of cytokines including IL-6, IL-8, CXCL1, and CXCL10.53 A randomized controlled clinical trial of 152 patients showed that patients who received fluvoxamine were less likely to experience clinical deterioration, or serious adverse events due to SARS-Cov-2 when compared to placebo (0% vs. 8%). A follow-up real-world observational cohort had similar findings of 0% (0/65) hospitalization with fluvoxamine vs. 12% (6/48) with observation.

Ivermectin has also shown anti-inflammatory effects that would reduce the harmful cytokine cascade noted in severe Covid-19 disease. A recent trial assessing a multi-therapy including 12mg one-time dose of ivermectin found a 75% reduction in hospitalizations. Another small double-blinded RCT showed significant increased chance of viral clearance after a 5-day course of ivermectin. Another March 2021 RCT reported no effect on diminishing symptoms, but was under-powered for assessing reductions in hospitalization. An RCT with ivermectin must be done in the US, as endemic strongyloidiasis in other countries may confound results.

Statistical Considerations:

An independent data safety monitoring board will assess safety approximately twice per month; and will assess futility and efficacy at least twice throughout the study. If one of the arms reaches pre-specified boundaries for futility or efficacy, the DSMB will recommend closing of that arm(s). The detailed statistical analysis plan will be developed by the blinded statistician and co-investigators and per the protocol will be submitted to the DSMB.

03

Conditions studied

  • Covid19
  • SARS-CoV Infection
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive laboratory test for active SARS-CoV-2 viral infection based on local laboratory standard (i.e. +PCR) within 3 days of randomization.
  • No known history of confirmed SARS-CoV-2 infection
  • >= 25kg/m2 by self-report height/weight or >= 23kg/m2 in patients who self-identify in South Asian or Latinx background.
  • Willing and able to comply with study procedures (i.e. swallow pills)
  • Has an address and electronic device for communication
  • >45ml/min within 2 weeks for patients >75 years old, or with history of heart, kidney, or liver failure.

Exclusion criteria

Exclusion Criteria:

  • Hospitalized, for COVID-19 or other reasons.
  • Symptom onset greater than 7 days before randomization (symptoms not required for inclusion).
  • Immune compromised state (solid organ transplant, bone marrow transplant, AIDS, on high dose )
  • Hepatic impairment ( B and C) or other condition that, in the opinion of the investigator, would affect safety
  • Inability to obtain
  • Enrollment in another blinded Randomized Controlled Trial for COVID-19
  • Already received an effective (FDA approved/EUA*) therapy for COVID-19 (currently monoclonal antibody treatment)
  • Alcohol use disorder
  • Other unstable medical condition or combination of home medications that in the view of the PI make it unsafe for the individual to participate
  • History of severe kidney disease i.e.:

    1. Stage 4 or 5 CKD, or Estimated (eGFR) of \< 45ml/min/1.73 m2
    2. Other kidney disease that in the opinion of the investigator would affect clearance
  • Unstable heart failure (Stage 3 or 4 heart failure)
  • Allergic reaction to metformin, fluvoxamine, or ivermectin in the past
  • Bipolar disease: individuals who report they have bipolar disorder or are taking medication for bipolar disorder (lithium, valproate, high-dose antipsychotic), unless the investigator concludes that the risk for mania is unlikely
  • Current loa loa or onchocerciasis infection
  • Typhoid, BCG, or cholera vaccination within the 14-days or 3 days after

Medication Exclusions:

  • Cimetidine, hydroxychloroquine, insulin, sulfonylurea, dolutegravir, patiromer, ranolazine, tafenoquine.
  • Rasagiline, selegiline, or monoamine oxidase inhibitors, linezolid, methadone
  • Duloxetine, methylene blue
  • Tizanidine, ramelteon, sodium picosulfate
  • Alosetron, agomelatine, bromopride, dapoxetine, tamsimelteon, thioridazine, urokinase, pimozide

The following medications may not need to be excluded when dose for that individual is considered alongside the low dose of fluvoxamine being used and other medications being used. The PI or site PI may review and decide if the patient should be excluded from the fluvoxamine arms:

  1. Taking SSRIs, SNRIs, or tricyclic antidepressants, unless these are at a low dose such that a study investigator concludes that a interaction with fluvoxamine (ie either serotonin syndrome or TCA overdose) is unlikely (examples: participant takes escitalopram but only at 10mg daily; that dose plus 100mg fluvoxamine would be insufficient to cause serotonin syndrome; or, participant takes amitriptyline but only at 25mg nightly; even if fluvoxamine inhibits its metabolism, it would be an insufficient dose to cause prolongation or problematic side effects). Risk Class C, monitor therapy.
  2. Individuals who take alprazolam or diazepam and are unwilling to cut the medication by 20% (rationale: fluvoxamine modestly inhibits the metabolism of these drugs). Risk Class C, monitor therapy
  3. Participants taking theophylline, clozapine, or olanzapine (drugs with a narrow therapeutic index that are primarily metabolized by CYP 1A2, which is inhibited by fluvoxamine) will be reviewed with a study investigator and excluded unless the investigator concludes that the risk to the participant is low (this would be unlikely; example: participant takes clozapine only as needed and is willing to avoid it for the 14 days of the study).
  4. Patients will be advised that there is a small risk that the following substances will be affected by fluvoxamine, but that significant effects are not likely at the low dose being used: caffeine, nicotine, melatonin. Risk Class C, monitor therapy
  5. Taking warfarin-also known as Coumadin, NSAIDs, and Aspirin (rationale: increased risk of bleeding), phenytoin (rationale: fluvoxamine inhibits its metabolism), clopidogrel (rationale: fluvoxamine inhibits its metabolism from pro-drug to active drug which raises risk of cardiovascular events), and St John's wort (rationale: fluvoxamine + St John's wort are considered because of the risk of serotonin syndrome) Risk C, monitor therapy.

    • Additional COVID-19 treatments to exclude will be decided by a panel of at least 3 Co-Investigators on this study. The additional treatments to exclude will be documented and submitted to the IRB but may be implemented before formal IRB approval is complete. We take this approach because of the rapidly changing treatment landscape of COVID-19. Participation in the study does not prevent them from receiving such treatments after enrollment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,323 participants (actual)

Study arms

  • Experimental
    Metformin + Placebo

    This is the randomization group that received active metformin + either fluvoxamine placebo or ivermectin placebo.

    Drug: Metformin · Drug: Placebo

  • Experimental
    Placebo

    This is the randomization group that received metformin placebo + either fluvoxamine placebo or ivermectin placebo.

    Drug: Placebo

  • Experimental
    Ivermectin + Metformin Placebo

    This is the randomization group that received active ivermectin + metformin placebo.

    Drug: Placebo · Drug: Ivermectin

  • Experimental
    Fluvoxamine + Metformin Placebo

    This is the randomization group that received active fluvoxamine + metformin placebo.

    Drug: Placebo · Drug: Fluvoxamine

  • Experimental
    Metformin + Fluvoxamine

    This is the randomization group that received active metformin + active fluvoxamine.

    Drug: Metformin · Drug: Fluvoxamine

  • Experimental
    Metformin + Ivermectin

    This is the randomization group that received active metformin + active ivermectin.

    Drug: Metformin · Drug: Ivermectin

Interventions

  • Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.

    Also known as: glucophage

  • DrugPlacebo

    placebo; appearance and size are exact matching to the three study drugs.

  • An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14

    Also known as: Luvox

  • An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days

    Also known as: Stromectol

06

What researchers measure

Primary outcomes

  1. Clinical Progression to Severe Covid

    Clinical progression, defined as Emergency department visit for any COVID-19 related symptom (including hospitalization or death) or decrease in O2 saturation (\<=93% on room air, or need for supplemental oxygen to maintain an O2 saturation \<=93%)

    Time frame: 14 Days

Secondary outcomes

  1. Clinical Progression to Severe Covid

    Emergency department visit for any COVID-19 related symptom (including hospitalization or death), active relative to placebo

    Time frame: 14 days

  2. Progression

    Count of participants with clinical progression to Hospitalization, Death

    Time frame: 28 days

  3. Maximum Symptom Severity

    Defined by adding the symptom score for each individual symptom on the "Daily Symptom Scale Recommended by FDA For Industry." Each symptom on the scale had an answer option ranging from 0 to 3. They corresponded to 0= no symptom; 1=mild symptom; 2=moderate symptom; 3=severe symptom. The range for the total score is 0 to 42 (14 symptoms x 3). The data presented here are the unadjusted mean (SD) for the total symptom score on Day 14.

    Time frame: 14 days

  4. Clinical Deterioration: Hospital and Vent >3days

    Progression to Hospitalization or Ventilation by Day 28

    Time frame: 28 days

  5. Laboratory Outcome Study

    Count of participants with no detectable viral load on Day 10.

    Time frame: Day5-Day10

  6. All-cause Study Medicine Discontinuation

    Study drug discontinuation (total interrupted - total restarted), per treatment allocation. Per treatment allocation means that these counts are not per randomized comparison.

    Time frame: 14 days

  7. Long Covid

    Proportion of participants with long-covid syndrome, PASC (post-acute sequelae of SARS-CoV-2 infection)

    Time frame: Day 300

07

Results

Posted Jul 13, 2023

Participant flow

Participant flow — Overall Study
MilestoneRandomization Arm - Metformin OnlyRandomization Arm - PlaceboRandomization Arm - Ivermectin OnlyRandomization Arm - Fluvoxamine OnlyRandomization Arm - Metformin and FluvoxamineRandomization Arm - Metformin and Ivermectin
Started284295206159175204
Completed278291206156173201
Not completed640323

Outcome measures

PrimaryClinical Progression to Severe Covid

Clinical progression, defined as Emergency department visit for any COVID-19 related symptom (including hospitalization or death) or decrease in O2 saturation (\<=93% on room air, or need for supplemental oxygen to maintain an O2 saturation \<=93%)

Time frame:
14 Days
Reported as:
Count of participants · Participants
Clinical Progression to Severe Covid
ParticipantsActive MetforminMetformin PlaceboActive IvermectinIvermectin PlaceboActive FluvoxamineFluvoxamine Placebo
Clinical Progression to Severe Covid154179105967980
SecondaryClinical Progression to Severe Covid

Emergency department visit for any COVID-19 related symptom (including hospitalization or death), active relative to placebo

Time frame:
14 days
Reported as:
Count of participants · Participants
Clinical Progression to Severe Covid
ParticipantsActive MetforminMetformin PlaceboActive IvermectinIvermectin PlaceboActive FluvoxamineFluvoxamine Placebo
Clinical Progression to Severe Covid274823161815
SecondaryProgression

Count of participants with clinical progression to Hospitalization, Death

Time frame:
28 days
Reported as:
Count of participants · Participants
Progression
ParticipantsActive MetforminMetformin PlaceboActive IvermectinIvermectin PlaceboActive FluvoxamineFluvoxamine Placebo
Progression8194565
SecondaryMaximum Symptom Severity

Defined by adding the symptom score for each individual symptom on the "Daily Symptom Scale Recommended by FDA For Industry." Each symptom on the scale had an answer option ranging from 0 to 3. They corresponded to 0= no symptom; 1=mild symptom; 2=moderate symptom; 3=severe symptom. The range for the total score is 0 to 42 (14 symptoms x 3). The data presented here are the unadjusted mean (SD) for the total symptom score on Day 14.

Time frame:
14 days
Reported as:
Mean · total score
Maximum Symptom Severity
total scoreActive MetforminMetformin PlaceboActive IvermectinIvermectin PlaceboActive FluvoxamineFluvoxamine Placebo
Maximum Symptom Severity3.48 ± 4.03.73 ± 4.293.45 ± 4.123.85 ± 4.283.53 ± 4.243.96 ± 4.46
SecondaryClinical Deterioration: Hospital and Vent >3days

Progression to Hospitalization or Ventilation by Day 28

Time frame:
28 days
Reported as:
Count of participants · Participants
Clinical Deterioration: Hospital and Vent >3days
ParticipantsActive MetforminMetformin PlaceboActive IvermectinIvermectin PlaceboActive FluvoxamineFluvoxamine Placebo
Clinical Deterioration: Hospital and Vent >3days7183565
SecondaryLaboratory Outcome Study

Count of participants with no detectable viral load on Day 10.

Time frame:
Day5-Day10
Reported as:
Count of participants · Participants
Laboratory Outcome Study
ParticipantsActive MetforminMetformin PlaceboActive IvermectinIvermectin PlaceboActive FluvoxamineFluvoxamine Placebo
Laboratory Outcome Study7211253454442
SecondaryAll-cause Study Medicine Discontinuation

Study drug discontinuation (total interrupted - total restarted), per treatment allocation. Per treatment allocation means that these counts are not per randomized comparison.

Time frame:
14 days
Reported as:
Count of participants · Participants
All-cause Study Medicine Discontinuation
ParticipantsRandomization Arm - Metformin Only GroupRandomization Arm - Placebo GroupRandomization Arm - Ivermectin Only GroupRandomization Arm - Fluvoxamine Only GroupRandomization Arm - Metformin and Fluvoxamine GroupRandomization Arm - Metformin and Ivermectin Group
All-cause Study Medicine Discontinuation564925325029
SecondaryLong Covid

Proportion of participants with long-covid syndrome, PASC (post-acute sequelae of SARS-CoV-2 infection)

Time frame:
Day 300
Reported as:
Count of participants · Participants
Long Covid
ParticipantsActive MetforminMetformin PlaceboActive IvermectinIvermectin PlaceboActive FluvoxamineFluvoxamine Placebo
Long Covid355930293022

Adverse events

Collected over Non-COVID adverse events were recorded through Day 14. Covid-related outcomes were recorded through Day 300.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomization Arm - Metformin Only0/284 (0%)0/284 (0%)0/284 (0%)
Randomization Arm - Placebo0/295 (0%)0/295 (0%)2/295 (0.7%)
Randomization Arm - Ivermectin Only0/206 (0%)0/206 (0%)1/206 (0.5%)
Randomization Arm - Fluvoxamine Only0/159 (0%)0/159 (0%)0/159 (0%)
Randomization Arm - Metformin and Fluvoxamine0/175 (0%)0/175 (0%)0/175 (0%)
Randomization Arm - Metformin and Ivermectin1/204 (0.5%)0/204 (0%)0/204 (0%)
Most frequent other events
Most frequent other events
EventRandomization Arm - Metformin OnlyRandomization Arm - PlaceboRandomization Arm - Ivermectin OnlyRandomization Arm - Fluvoxamine OnlyRandomization Arm - Metformin and FluvoxamineRandomization Arm - Metformin and Ivermectin
neuropathyNervous system disorders0/2840/2951/2060/1590/1750/204
dizzinessGeneral disorders0/2841/2950/2060/1590/1750/204
weakness in leg/armsMusculoskeletal and connective tissue disorders0/2841/2950/2060/1590/1750/204

Baseline characteristics

Age, Continuous
Age, Continuous(years)Randomization Arm - Metformin OnlyRandomization Arm - PlaceboRandomization Arm - Ivermectin OnlyRandomization Arm - Fluvoxamine OnlyRandomization Arm - Metformin and FluvoxamineRandomization Arm - Metformin and IvermectinTotal
Mean46 (36 to 56)42 (36 to 54)48 (39 to 57)46 (38 to 53)46 (38 to 53)46 (39 to 53)46 (37 to 55)
Sex: Female, Male
Sex: Female, Male(Participants)Randomization Arm - Metformin OnlyRandomization Arm - PlaceboRandomization Arm - Ivermectin OnlyRandomization Arm - Fluvoxamine OnlyRandomization Arm - Metformin and FluvoxamineRandomization Arm - Metformin and IvermectinTotal
Female1681871088783108741
Male11610898729296582
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Randomization Arm - Metformin OnlyRandomization Arm - PlaceboRandomization Arm - Ivermectin OnlyRandomization Arm - Fluvoxamine OnlyRandomization Arm - Metformin and FluvoxamineRandomization Arm - Metformin and IvermectinTotal
American Indian or Alaska Native44441118
Asian79654738
Native Hawaiian or Other Pacific Islander1200115
Black or African American20151213141387
White2132381511251411541022
More than one race104542530
Unknown or Not Reported29232881223123
08

Study locations

7 sites
  • Olive View UCLA Medical Center
    Sylmar, California 91342, United States
  • University of Colorado Denver; Department of Medicine; Anschutz Health and Wellness Center
    Aurora, Colorado 80045, United States
  • New West Physicians
    Golden, Colorado 80401, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • American Health Network of Indiana
    Greenfield, Indiana 46140, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
09

References and documents

Publications

  • Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Huttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O'Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d'Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, Garcia-Sastre A, Shokat KM, Shoichet BK, Krogan NJ. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30. PubMed 32353859 ↗
  • Castle, B.T., C. Dock, M. Hemmat, S. Kline, C. Tignanelli, R. Rajasingham, D. Masopust, P. Provenzano, R. Langlois, T. Schacker, A. Haase, and D.J. Odde, Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets. bioRxiv, 2020. https://www.biorxiv.org/content/10.1101/2020.05.22.111237v2.
  • Hartman KM, Patel B, Rao V, Hagen AA, Saveraid HG, Fricton R, Lee S, Snyder AT, Pullen MF, Boulware DR, Liebovitz DM, Belani HK, Niklas JM, Murray TA, Cohen K, Thompson JL, Erickson SM, Bramante CT. A Comparison of Recruitment Methods for a Remote, Nationwide Clinical Trial for COVID-19 Treatment. Open Forum Infect Dis. 2024 Apr 29;11(7):ofae224. doi: 10.1093/ofid/ofae224. eCollection 2024 Jul. PubMed 38947738 ↗
  • Bramante CT, Beckman KB, Mehta T, Karger AB, Odde DJ, Tignanelli CJ, Buse JB, Johnson DM, Watson RHB, Daniel JJ, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Siegel LK, Klatt NR, Anderson B, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Fricton RD, Lee S, Griffiths G, Pullen MF, Thompson JL, Sherwood NE, Murray TA, Rose MR, Boulware DR, Huling JD; COVID-OUT Study Team. Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19. Clin Infect Dis. 2024 Aug 16;79(2):354-363. doi: 10.1093/cid/ciae159. PubMed 38690892 ↗
  • Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, Belani HK, Anderson BJ, Huling JD, Tignanelli CJ, Thompson JL, Pullen M, Wirtz EL, Siegel LK, Proper JL, Odde DJ, Klatt NR, Sherwood NE, Lindberg SM, Karger AB, Beckman KB, Erickson SM, Fenno SL, Hartman KM, Rose MR, Mehta T, Patel B, Griffiths G, Bhat NS, Murray TA, Boulware DR; COVID-OUT Study Team. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023 Oct;23(10):1119-1129. doi: 10.1016/S1473-3099(23)00299-2. Epub 2023 Jun 8. PubMed 37302406 ↗
  • Boulware DR, Murray TA, Proper JL, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Siegel LK, Klatt NR, Odde DJ, Karger AB, Ingraham NE, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Lindberg S, Fricton R, Lee S, Zaman A, Saveraid HG, Tordsen WJ, Pullen MF, Sherwood NE, Huling JD, Bramante CT; COVID-OUT study team. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial. Clin Infect Dis. 2023 Feb 8;76(3):e1-e9. doi: 10.1093/cid/ciac772. PubMed 36124697 ↗
  • Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Proper JL, Siegel LK, Klatt NR, Odde DJ, Luke DG, Anderson B, Karger AB, Ingraham NE, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Lindberg S, Fricton R, Lee S, Zaman A, Saveraid HG, Tordsen WJ, Pullen MF, Biros M, Sherwood NE, Thompson JL, Boulware DR, Murray TA; COVID-OUT Trial Team. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022 Aug 18;387(7):599-610. doi: 10.1056/NEJMoa2201662. PubMed 36070710 ↗
  • Dodds MG, Doyle EB, Reiersen AM, Brown F, Rayner CR. Fluvoxamine for the treatment of COVID-19. Lancet Glob Health. 2022 Mar;10(3):e332. doi: 10.1016/S2214-109X(22)00006-7. No abstract available. PubMed 35180412 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Dec 2022, 23 months.

Results were first posted in Jul 2023, 6 months after primary completion.

Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 23 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2020
First posted
Aug 12, 2020
StartActual
Jan 1, 2021
Primary completionActual
Dec 14, 2022
CompletionActual
Dec 14, 2022
Results first posted
Jul 13, 2023
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04510194
Collaborators
UnitedHealth Group, Northwestern University, Hennepin County Medical Center, Minneapolis, University of Colorado, Denver, Olive View-UCLA Education & Research Institute
Responsible party
Sponsor
First posted
Aug 12, 2020
Start date
Jan 1, 2021
Primary completion
Dec 14, 2022
Completion
Dec 14, 2022
Results posted
Jul 13, 2023
Last update
Apr 24, 2026

Study contacts

Carolyn Bramante, MD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Fluvoxamine · Ivermectin

Start the discussion